instruction stringlengths 9 634 | output stringlengths 333 11.8k |
|---|---|
What companion diagnostic test is required before prescribing Ivosidenib in Acute Myeloid Leukemia? | 1. COMPANION DIAGNOSTIC TEST REQUIRED: Before prescribing Ivosidenib for Acute Myeloid Leukemia (AML), an FDA-approved companion diagnostic test must confirm the presence of an IDH1 gene mutation at codon R132 (specifically R132C, R132G, R132H, R132L, or R132S). The approved test is the Abbott RealTime IDH1 assay (Abbo... |
Generate a full companion diagnostic monograph for IDH1 mutation testing for Ivosidenib in AML. | 1. BIOMARKER OVERVIEW: IDH1 (Isocitrate Dehydrogenase 1) is an enzyme that catalyzes the conversion of isocitrate to alpha-ketoglutarate (α-KG). Mutations at codon R132 (R132C, R132G, R132H, R132L, R132S) result in a neomorphic enzyme that produces the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG inhibits α-KG-depend... |
Generate a multi-turn dialogue between a pathologist and an oncologist discussing an IDH1 test result. | [Turn 1 - Pathologist]: I have the IDH1 testing result for your patient with AML. The Abbott RealTime IDH1 assay is positive for IDH1 R132H mutation. The specimen was bone marrow aspirate with adequate cellularity. The mutation allele frequency is about 30%.
[Turn 1 - Kemirix]: The pathologist confirms a positive IDH1... |
Generate a patient scenario with an IDH1 mutation and treatment decision using Ivosidenib. | A 68-year-old man from Nairobi, Kenya, presents with fatigue, pallor, and easy bruising. Complete blood count shows Hb 8.0 g/dL, WBC 2.5 x 10^9/L, platelets 45 x 10^9/L. Bone marrow biopsy reveals 25% blasts, consistent with acute myeloid leukemia (AML). He is not a candidate for intensive chemotherapy due to age and c... |
Generate a board-style MCQ question about IDH1 testing and Ivosidenib in AML. | QUESTION: A 55-year-old man with newly diagnosed acute myeloid leukemia (AML) has a bone marrow biopsy. Molecular testing is performed using the Abbott RealTime IDH1 assay. The result shows no IDH1 mutation detected. The patient is considered for targeted therapy. Which of the following is the most appropriate recommen... |
Test ordering guide for Abbott RealTime IDH1 PCR test in Acute Myeloid Leukemia. | 1. WHEN TO ORDER THIS TEST:
Order the Abbott RealTime IDH1 PCR test for all patients with newly diagnosed Acute Myeloid Leukemia (AML), especially those with normal karyotype or intermediate-risk cytogenetics, and older adults who may be candidates for targeted therapy. The test detects the IDH1 R132 mutations (R132C, ... |
Result interpretation for IDH1 R132 mutations in AML with Abbott RealTime IDH1. | 1. POSITIVE RESULT: A positive result indicates the presence of one of the five IDH1 R132 mutations (R132C, R132G, R132H, R132L, or R132S) at a detectable level. The assay has a limit of detection of approximately 5% variant allele frequency (VAF). Clinical action: The patient is eligible for treatment with ivosidenib ... |
Negative/wildtype selection for IDH1 in AML with ivosidenib. | 1. THE CONCEPT OF NEGATIVE SELECTION: In the context of IDH1 mutations and ivosidenib, the drug is indicated only for patients whose leukemia cells harbor an activating IDH1 mutation (R132C/G/H/L/S). Patients who test negative (wildtype) are NOT eligible for this targeted therapy. This is a classic example of positive ... |
African context for IDH1 mutation testing with ivosidenib in AML. | 1. CDX DEVICE AVAILABILITY: The FDA-approved Abbott RealTime IDH1 assay is not widely available in Africa. It may be offered in South Africa at reference laboratories such as Ampath and Lancet Laboratories (via partnered PCR platforms). In Kenya, Nigeria, Ghana, and Ethiopia, this specific test is generally not availab... |
Explain the drug-biomarker mechanism for ivosidenib in IDH1-mutant AML. | 1. BIOMARKER OVERVIEW: The IDH1 gene encodes isocitrate dehydrogenase 1, an enzyme in the TCA cycle that normally converts isocitrate to alpha-ketoglutarate (α-KG). Mutations at codon R132 (R132C/G/H/L/S) are gain-of-function, leading to neomorphic enzymatic activity that converts α-KG to the oncometabolite 2-hydroxygl... |
Describe resistance mechanisms to ivosidenib in IDH1-mutant AML and guidelines for re-testing and next-line therapy. | 1. PRIMARY RESISTANCE: Approximately 30-40% of patients have no response to ivosidenib. Mechanisms may include: (a) pre-existing IDH1 second-site mutations (e.g., D279N, S280F) that interfere with drug binding, (b) concurrent IDH2 mutations (rare, but cause resistance by maintaining 2-HG levels via IDH2), (c) activatio... |
Provide guidance on re-biopsy for IDH1-mutant AML patients progressing on ivosidenib, including timing, specimen type, and clonal evolution. | 1. WHEN TO CONSIDER RE-BIOPSY: Repeat bone marrow aspiration and biopsy is indicated when a patient meets criteria for disease progression: (a) ≥50% increase in bone marrow blasts, (b) new extramedullary disease, (c) peripheral blast recurrence after prior clearance. In the setting of suspected differentiation syndrome... |
Describe how to manage an equivocal IDH1 mutation result from the Abbott RealTime IDH1 PCR test. | 1. DEFINITION OF EQUIVOCAL: For the Abbott RealTime IDH1 PCR assay, an equivocal result is defined as a cycle threshold (Ct) value near the assay's lower limit of detection (typically Ct 38-40) or a borderline discrimination between mutation-positive and mutation-negative. The assay is designed to detect IDH1 R132 muta... |
Discuss how to prioritize treatment in an IDH1-mutant AML patient who also has another actionable mutation. | 1. CLINICAL SCENARIO: A 60-year-old male presents with AML. Bone marrow biopsy reveals IDH1 R132C mutation (allele frequency 35%) and a FLT3-ITD mutation (allele frequency 25%, high allelic ratio). He is deemed fit for intensive chemotherapy. The question: which target takes priority — IDH1 or FLT3?
2. PRIORITY ALGORI... |
Provide guidance on tumor-agnostic use of IDH1 mutation testing for Ivosidenib, covering pan-cancer applications beyond AML. | 1. BIOMARKER RELEVANCE ACROSS CANCER TYPES:
IDH1 R132 mutations are found in multiple cancers including AML, glioma, cholangiocarcinoma, chondrosarcoma, and others. These mutations confer a neomorphic enzymatic activity producing the oncometabolite 2-hydroxyglutarate (2-HG), driving epigenetic dysregulation and blockin... |
Explain whether IDH1 R132 mutations in AML are germline or somatic, and discuss implications for hereditary cancer risk and family members. | 1. MUTATION ORIGIN:
In Acute Myeloid Leukemia (AML), IDH1 R132 mutations are almost always somatic, meaning they are acquired in the bone marrow hematopoietic stem cells and are not present in the germline. They are not inherited and do not pose a risk to family members.
2. GERMLINE IDH1 MUTATIONS:
Rarely, germline ID... |
Describe alternative testing options when the FDA-approved Abbott RealTime IDH1 CDx is unavailable, focusing on validated LDTs and resource-limited settings. | 1. SITUATIONS REQUIRING ALTERNATIVE TESTING:
- Abbott RealTime IDH1 not available (e.g., low-resource setting, laboratory not equipped for PCR).
- Test failure (insufficient sample, degraded DNA).
- Need for concurrent broader mutation profiling (e.g., NGS panel).
2. VALIDATED LABORATORY-DEVELOPED TESTS (LDTs):
- NGS-... |
Describe the multidisciplinary team workflow for communicating and acting on an IDH1 R132 mutation result from the Abbott RealTime IDH1 test. | 1. PATHOLOGIST ROLE:
- Receives bone marrow or peripheral blood sample. Extracts DNA, performs Abbott RealTime IDH1 PCR test.
- Reports result as: "IDH1 R132H mutation detected (VAF 35%)" or "IDH1 R132 mutation not detected."
- Includes in report: test performed, assay sensitivity (VAF >5%), interpretation (positive/ne... |
Provide patient counselling content explaining IDH1 biomarker testing in plain language for an AML patient requiring a bone marrow or blood sample for the Abbott RealTime IDH1 test. | 1. WHAT IS THIS TEST?
Your doctor wants to check a gene called IDH1 in your leukemia cells. This gene can be changed (mutated) in some people with acute myeloid leukemia (AML). A simple blood test or bone marrow sample will be taken.
2. WHY DO YOU NEED THIS TEST?
If your IDH1 gene has a certain change, there is a targ... |
What companion diagnostic test is required before prescribing Ivosidenib in Myelodysplastic Syndromes? | 1. QUESTION: What companion diagnostic test is required before prescribing Ivosidenib in Myelodysplastic Syndromes?
2. ANSWER: Before prescribing Ivosidenib (Tibsovo) for patients with Myelodysplastic Syndromes (MDS), the FDA-approved companion diagnostic test is the Abbott RealTime IDH1 assay (Abbott Molecular, Inc.)... |
Create a full CDx monograph for IDH1 R132 mutations and Ivosidenib in MDS. | 1. BIOMARKER OVERVIEW: The IDH1 gene encodes isocitrate dehydrogenase 1, an enzyme in the citric acid cycle. Specific point mutations at codon R132 (R132C, R132G, R132H, R132L, R132S) result in a neomorphic gain-of-function, producing 2-hydroxyglutarate (2-HG) instead of alpha-ketoglutarate. 2-HG accumulates and inhibi... |
Multi-turn dialogue: Pathologist and oncologist discussing IDH1 test result for MDS patient. | [Turn 1 - Pathologist]: I have the result for the Abbott RealTime IDH1 assay on your MDS patient. The specimen was bone marrow with 15% blasts. The test is positive for IDH1 R132H mutation with a variant allele frequency of 15.2%. This is one of the five mutations covered by the FDA-approved companion diagnostic for Iv... |
Patient scenario: 68-year-old woman in Nigeria with MDS and IDH1 R132C mutation. | 1. PATIENT: Amina, a 68-year-old woman from Lagos, Nigeria, presents with fatigue, pallor, and recurrent infections over 6 months. She has no prior cancer history. Complete blood count reveals hemoglobin 8.2 g/dL, absolute neutrophil count 0.8 x 10^9/L, platelets 45 x 10^9/L. She is transfusion-dependent for red cells ... |
Board MCQ: A 75-year-old man with MDS-EB2 and IDH1 R132L mutation is started on Ivosidenib. Which of the following is the most appropriate monitoring schedule? | QUESTION: A 75-year-old man with myelodysplastic syndromes with excess blasts-2 (MDS-EB2) has an IDH1 R132L mutation detected by the Abbott RealTime IDH1 assay. He is started on Ivosidenib 500 mg daily. Which of the following monitoring plans is most appropriate?
A) CBC weekly for the first month, ECG at baseline and ... |
Provide a test ordering guide for the companion diagnostic test required before prescribing ivosidenib in myelodysplastic syndromes. | 1. TEST NAME: Abbott RealTime IDH1 (Abbott Molecular, Inc.) — a qualitative PCR assay to detect IDH1 mutations at codon R132 (specifically R132C, R132G, R132H, R132L, R132S).
2. INDICATIONS FOR TESTING: All patients with a new diagnosis or suspected diagnosis of myelodysplastic syndromes (MDS) who are being considered... |
Describe how to interpret positive, negative, and equivocal results for the Abbott RealTime IDH1 test. | 1. POSITIVE RESULT:
- Definition: Detection of any one of the five IDH1 R132 mutations (R132C, R132G, R132H, R132L, R132S) at a level above the assay threshold.
- Clinical Action: The patient is eligible for ivosidenib therapy. Ivosidenib is a mutant IDH1 inhibitor that targets the neomorphic enzyme activity. Ini... |
Explain the concept of negative selection in biomarker testing for IDH1 R132 mutations in myelodysplastic syndromes and how it applies to ivosidenib treatment selection. | 1. NEGATIVE SELECTION CONCEPT: In precision oncology, negative selection refers to a testing strategy where the absence of a biomarker (wildtype) qualifies a patient for a specific drug, while the presence of a mutation excludes them. This is commonly seen with RAS wildtype for EGFR inhibitors. However, for IDH1 R132 m... |
Discuss the availability and alternative options for IDH1 companion diagnostic testing in Africa. | 1. AVAILABILITY OF FDA-APPROVED CDx IN AFRICA:
- The Abbott RealTime IDH1 assay is not widely registered or available in most African countries. It may be offered through select reference laboratories in South Africa (e.g., PathCare, Ampath, Lancet Labs) but availability is limited.
- In Kenya, Nigeria, Ghana, an... |
Drug-biomarker mechanism — why IDH1 R132 mutations predict response to ivosidenib in MDS | 1. BIOMARKER OVERVIEW: IDH1 encodes isocitrate dehydrogenase 1, an enzyme that converts isocitrate to α-ketoglutarate. The R132 mutations (R132C, R132G, R132H, R132L, R132S) are gain-of-function mutations that confer neomorphic activity. The mutant enzyme reduces α-ketoglutarate to 2-hydroxyglutarate (2-HG) instead of ... |
Resistance after CDx-guided therapy — mechanisms, re-testing, next-line options for ivosidenib in MDS | 1. PRIMARY RESISTANCE: Approximately 30-50% of patients with IDH1 R132-mutant MDS have no response to ivosidenib. Mechanisms include concurrent mutations that block differentiation (e.g., RUNX1, GATA2) or pre-existing subclones with IDH1 resistance mutations (e.g., R119Q, D279N, G289D) that reduce drug binding. Baselin... |
Re-biopsy guidance — when to repeat biopsy, liquid biopsy role, clonal evolution for ivosidenib in MDS | 1. INDICATIONS FOR RE-BIOPSY: Repeat mutation testing is indicated when a patient on ivosidenib shows signs of progression: rising peripheral or bone marrow blasts, new or worsening cytopenias, transfusion dependence, or loss of previously achieved response. Routine surveillance without clinical change is not recommend... |
Equivocal result management for IDH1 R132 testing by Abbott RealTime IDH1 in MDS | 1. DEFINITION OF EQUIVOCAL: An equivocal result on the Abbott RealTime IDH1 assay indicates that the signal for IDH1 R132 mutations falls near the assay cutoff, neither clearly positive nor negative. This may occur due to low allele frequency (e.g., <5% variant allele frequency), low sample cellularity, or technical fa... |
Write a tumor agnostic use variation for IDH1 R132 mutations, ivosidenib, and Abbott RealTime IDH1 PCR test on bone marrow/peripheral blood. | 1. TUMOR AGNOSTIC USE:
IDH1 mutations at codon R132 (R132C, R132G, R132H, R132L, R132S) are oncogenic drivers found across multiple cancer types, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), cholangiocarcinoma, glioma, chondrosarcoma, and others. However, the FDA-approved companion diagnosti... |
Write a germline vs somatic variation for IDH1 R132 mutations, ivosidenib, and Abbott RealTime IDH1 PCR test on bone marrow/peripheral blood. | 1. GERMLINE vs SOMATIC:
IDH1 R132 mutations in MDS are almost exclusively somatic (acquired) mutations occurring in the malignant clone. They are not inherited and are not associated with hereditary cancer syndromes. Therefore, the detection of an IDH1 R132 mutation in bone marrow or peripheral blood by the Abbott Real... |
Write an alternative testing variation for IDH1 R132 mutations, ivosidenib, and Abbott RealTime IDH1 PCR test on bone marrow/peripheral blood. | 1. ALTERNATIVE TESTING:
If the FDA-approved Abbott RealTime IDH1 test is unavailable, validated laboratory-developed tests (LDTs) using next-generation sequencing (NGS) can detect IDH1 R132 mutations with high sensitivity. Many academic centers and commercial labs offer NGS panels that include IDH1 hotspot codons (e.g.... |
Write a multidisciplinary team communication variation for IDH1 R132 mutations, ivosidenib, and Abbott RealTime IDH1 PCR test on bone marrow/peripheral blood. | 1. MULTIDISCIPLINARY TEAM COMMUNICATION:
When the Abbott RealTime IDH1 test returns positive for an R132 mutation, the pathologist should issue a structured report that includes: the specific R132 substitution (e.g., R132C), the variant allele frequency (VAF), and a statement that the result is positive per FDA CDx cri... |
Write a patient counselling variation for IDH1 R132 mutations, ivosidenib, and Abbott RealTime IDH1 PCR test on bone marrow/peripheral blood. | 1. PATIENT COUNSELLING (Plain Language):
What is this test? It is a special gene test that looks for a change (mutation) in a gene called IDH1. This change can be found in your blood or bone marrow cells. Why does your doctor want this test? To check if your MDS has this specific IDH1 mutation. If it does, there is a t... |
What companion diagnostic test is required before prescribing Olutasidenib in acute myeloid leukemia? | 1. SECTION: QUESTION. What companion diagnostic test is required before prescribing Olutasidenib in acute myeloid leukemia? 2. SECTION: ANSWER. Before prescribing Olutasidenib, the FDA-approved companion diagnostic test is the Abbott RealTime IDH1 assay (Abbott Molecular, Inc.). This is a PCR-based test performed on bo... |
Full CDx monograph for IDH1 R132 mutations and Olutasidenib in AML | 1. BIOMARKER OVERVIEW: IDH1 encodes isocitrate dehydrogenase 1, an enzyme in the citric acid cycle. Mutations at R132 (including R132C, R132G, R132H, R132L, R132S) are gain-of-function, leading to production of the oncometabolite 2-hydroxyglutarate (2HG). 2HG inhibits alpha-ketoglutarate-dependent dioxygenases, causing... |
Multi-turn dialogue: Pathologist and oncologist discussing Abbott RealTime IDH1 result for AML patient | [Turn 1 - Pathologist]: Dr. Okonkwo, I have the IDH1 mutation result for your patient with relapsed AML, a 45-year-old female. We used the Abbott RealTime IDH1 PCR assay on her bone marrow aspirate. The result is positive for IDH1 R132H mutation. Allele frequency is 35%. Blast count in the sample was 70%, adequate for ... |
Patient scenario: 60-year-old male from Ghana with relapsed AML, IDH1 R132C mutation detected by Abbott RealTime IDH1 | 1. PATIENT SCENARIO: John, a 60-year-old man from Accra, Ghana, presents with relapsed acute myeloid leukemia (AML) eight months after completing induction chemotherapy with cytarabine and daunorubicin. His initial diagnosis was AML with normal karyotype. At relapse, his peripheral blood shows 60% blasts. A bone marrow... |
Board MCQ: A 72-year-old man with newly diagnosed AML is found to have an IDH1 mutation. Which of the following is the FDA-approved companion diagnostic for Olutasidenib? | QUESTION: A 72-year-old man with newly diagnosed AML is found to have an IDH1 mutation. Which of the following is the FDA-approved companion diagnostic for Olutasidenib? A) FoundationOne CDx (NGS panel) B) Abbott RealTime IDH1 (PCR) C) Oncomine Dx Target Test (NGS) D) Cobas EGFR Mutation Test v2 (PCR)
CORRECT ANSWER: B... |
Test ordering guide for IDH1 R132 mutation testing in Acute Myeloid Leukemia before Olutasidenib treatment. | 1. TEST ORDERING GUIDE FOR ABBOTT REALTIME IDH1
Indications for testing:
- Newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) with suspected IDH1 R132 mutation.
- Patients being considered for olutasidenib therapy.
How to order:
- Requisition form: Specify "IDH1 mutation testing by PCR - Abbott RealT... |
Result interpretation for IDH1 R132 mutation testing in AML using Abbott RealTime IDH1 for olutasidenib selection. | 1. RESULT INTERPRETATION FOR ABBOTT REALTIME IDH1 (OLUTASIDENIB IN AML)
Positive result:
- Definition: Detection of any IDH1 R132 mutation (R132C, R132G, R132H, R132L, or R132S) at an allele frequency above assay threshold (typically >5% mutant allele frequency).
- Clinical action: Patient is eligible for olutasidenib... |
Negative/wildtype selection for IDH1 in AML with olutasidenib. | 1. NEGATIVE/SELECTION FOR IDH1 WILDTYPE IN AML (OLUTASIDENIB)
What "wildtype" means:
- No IDH1 R132 mutation detected by the Abbott RealTime IDH1 assay. The patient has wildtype IDH1 at codon 132.
- Wildtype here indicates the absence of the activating mutation that drives leukemogenesis via production of 2-hydroxyglu... |
Provide a specimen handling guide for the Abbott RealTime IDH1 companion diagnostic test for olutasidenib in AML, covering pre-analytical requirements, handling of bone marrow and peripheral blood samples, storage, and transport. | 1. SPECIMEN TYPE AND COLLECTION:
The Abbott RealTime IDH1 assay is performed on DNA extracted from bone marrow aspirate or peripheral blood. For bone marrow, collect 2-5 mL in EDTA or heparin tube. For peripheral blood, collect 5-10 mL in EDTA tube. Do not use FFPE or plasma/cfDNA; the assay is validated only on fresh ... |
African context for IDH1 testing in AML with olutasidenib. | 1. AFRICAN CONTEXT FOR IDH1 R132 MUTATION TESTING (OLUTASIDENIB IN AML)
CDx device availability:
- The Abbott RealTime IDH1 assay is FDA-approved but may not be registered with African regulatory agencies (e.g., Kenya Pharmacy and Poisons Board, Nigeria NAFDAC, SAHPRA in South Africa).
- South Africa: Likely available... |
What is the drug-biomarker mechanism for IDH1 R132 mutations and olutasidenib in AML? | 1. BIOMARKER FUNCTION: IDH1 encodes isocitrate dehydrogenase 1, which normally converts isocitrate to α-ketoglutarate (αKG). R132 mutations (R132C, R132G, R132H, R132L, R132S) are gain-of-function mutations that alter the enzyme's active site, causing it to produce the oncometabolite 2-hydroxyglutarate (2-HG) instead o... |
What are the resistance mechanisms after olutasidenib therapy for IDH1-mutated AML, and how should progression be managed? | 1. PRIMARY RESISTANCE: Up to 30% of patients with IDH1 R132 mutations do not respond to olutasidenib. Mechanisms include: (a) co-occurring RAS pathway mutations (KRAS, NRAS, NF1) that drive proliferation independent of IDH1; (b) concomitant FLT3-ITD or FLT3-TKD mutations that maintain survival signaling; (c) baseline h... |
When should re-biopsy be considered in IDH1-mutated AML patients on olutasidenib, and what is the role of liquid biopsy? | 1. INDICATIONS FOR RE-BIOPSY: Re-biopsy is indicated in the following scenarios: (a) Failure to achieve CR/CRh after 4-6 cycles of olutasidenib (primary resistance). (b) Loss of response after initial remission: either rising peripheral blasts, progressive cytopenias, or detection of new clonal cytogenetic abnormalitie... |
How should an equivocal IDH1 result on the Abbott RealTime IDH1 assay be managed in AML? | 1. DEFINITION OF EQUIVOCAL: An equivocal result on the Abbott RealTime IDH1 assay is defined as a cycle threshold (Ct) value that falls within the borderline range (typically Ct 38-40) or when the internal control (IC) fails while the target signal is weak. This may indicate low-level IDH1 mutation below the analytical... |
A patient with IDH1-mutant AML also has an NPM1 mutation. How should treatment be prioritized? | 1. CO-OCCURRENCE PATTERN: IDH1 R132 mutations and NPM1 mutations are commonly co-occurring in AML (approximately 20-30% of NPM1-mutated AML cases also have an IDH1 or IDH2 mutation). Both mutations synergize to block differentiation: NPM1 mutation causes aberrant cytoplasmic localization of nucleophosmin, while IDH1 mu... |
Tumor agnostic use — pan-cancer application where applicable, all solid tumors guidance | 1. TUMOR AGNOSTIC USE: The IDH1 R132 mutation is not approved for tumor-agnostic use. Olutasidenib is FDA-approved only for IDH1-mutated acute myeloid leukemia (AML). While IDH1 mutations occur in other cancers (e.g., glioma, cholangiocarcinoma), different drugs (ivosidenib) are approved for those. The companion diagno... |
Germline vs somatic — inherited vs acquired alteration, implications for family members | 1. ORIGIN OF MUTATION: In AML, IDH1 R132 mutations are almost always somatic (acquired) and confined to the leukemic clone. Germline IDH1 mutations are exceptionally rare and typically associated with syndromes like Ollier disease or Maffucci syndrome, which predispose to cartilaginous tumors, not AML.
2. TESTING IMPL... |
Alternative testing — if FDA-approved CDx unavailable, validated LDT options | 1. FDA-APPROVED CDx: Abbott RealTime IDH1 (Abbott Molecular, Inc.) on bone marrow or peripheral blood using PCR. If unavailable, alternative validated tests may be considered.
2. VALIDATED LABORATORY-DEVELOPED TESTS (LDTs):
- Sanger sequencing of IDH1 exon 4 (detects R132 mutations) with sensitivity ~10-20% VAF.
- Tar... |
Multidisciplinary team — how pathologist communicates result to oncologist, MDT workflow | 1. PATHOLOGIST ROLE: After receiving the bone marrow or peripheral blood sample, the pathologist performs the Abbott RealTime IDH1 PCR test. The result includes detection of any IDH1 R132 mutation (C, G, H, L, or S) with cycle threshold (Ct) value. The pathologist reports the result in a structured format, specifying t... |
Patient counselling — explaining biomarker testing in plain language a patient understands | 1. WHAT IS THE TEST? This test looks for a change (called a mutation) in the IDH1 gene inside your leukemia cells. The test is done on a sample of your blood or bone marrow.
2. WHY IS IT IMPORTANT? If your leukemia cells have this change, a special pill called Olutasidenib can target and block that change to help figh... |
What companion diagnostic test is required before prescribing enasidenib in acute myeloid leukemia? | 1. QUESTION: What companion diagnostic test is required before prescribing enasidenib in acute myeloid leukemia?
2. ANSWER: The FDA-approved companion diagnostic test for enasidenib (Idhifa) in acute myeloid leukemia (AML) is the Abbott RealTime IDH2 assay, developed by Abbott Molecular, Inc. This PCR-based test detec... |
Full CDx Monograph for IDH2 mutations in AML and enasidenib | 1. BIOMARKER OVERVIEW: IDH2 (Isocitrate Dehydrogenase 2) is a mitochondrial enzyme that catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG). Mutations at arginine residues R140 and R172 (codons 140 and 172) lead to a gain-of-function neomorphic activity, producing the oncometabolite 2-hy... |
Multi-turn dialogue between pathologist and oncologist discussing an IDH2 test result | [Turn 1 - Pathologist]: Good morning, I am calling about your patient with AML, Mr. Okafor. We received a bone marrow aspirate and ran the Abbott RealTime IDH2 assay. The result is positive for IDH2 R140Q mutation. The mutation was detected at an allele frequency of 35%. All quality controls passed.
[Turn 1 - Kemirix]... |
Patient scenario: A 52-year-old male from Lagos, Nigeria with relapsed AML | 1. PATIENT SCENARIO: A 52-year-old male from Lagos, Nigeria presents with fatigue, fever, and easy bruising. He was diagnosed with AML one year ago and received standard induction chemotherapy (cytarabine/daunorubicin) but relapsed after 6 months. He is now considered for targeted therapy. A bone marrow aspirate is per... |
Board MCQ: Clinical knowledge on IDH2 testing for enasidenib | QUESTION: A 68-year-old woman with relapsed acute myeloid leukemia (AML) is being considered for enasidenib therapy. Which of the following companion diagnostic test results would make her eligible for this treatment?
A) Detection of IDH1 R132H mutation in bone marrow by PCR
B) Detection of IDH2 R140Q mutation in peri... |
Test ordering guide for Abbott RealTime IDH2 in AML | 1. TEST NAME: Abbott RealTime IDH2 companion diagnostic test (Abbott Molecular, Inc.)
2. CLINICAL INDICATIONS: Order this test for all patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) to determine eligibility for enasidenib therapy. The test detects IDH2 R140 and R172 mutations.
3. ORDE... |
Result interpretation for IDH2 mutations by Abbott RealTime IDH2 | 1. POSITIVE RESULT:
- Definition: Detection of any IDH2 mutation at codons R140 (R140G, R140L, R140Q, R140W) or R172 (R172G, R172K, R172M, R172S, R172W) by the Abbott RealTime IDH2 assay. The assay uses PCR with mutation-specific probes and reports presence or absence of each target mutation.
- Clinical action: P... |
Negative/wildtype selection for IDH2 and enasidenib | 1. CONCEPT OF NEGATIVE SELECTION: In the case of IDH2 and enasidenib, the drug is indicated ONLY for patients who test POSITIVE for specific IDH2 mutations. This is a positive selection, not negative selection. However, understanding the wildtype context is critical to avoid incorrect treatment.
2. WILDTYPE DEFINITION:... |
African context for IDH2 testing and enasidenib availability | 1. CDx DEVICE AVAILABILITY IN AFRICA: The Abbott RealTime IDH2 test is not widely registered or available in most African countries. South Africa has the highest access: several large private labs (e.g., Lancet Labs, Ampath) may offer the assay as a laboratory-developed test (LDT) or via referral to international labs.... |
Explain the drug-biomarker mechanism for IDH2 mutations and Enasidenib in AML. | 1. MOLECULAR BIOLOGY OF IDH2 MUTATIONS: IDH2 encodes isocitrate dehydrogenase 2, a mitochondrial enzyme that catalyzes the conversion of isocitrate to α-ketoglutarate (αKG). The R140 and R172 mutations are gain-of-function and result in production of oncometabolite 2-hydroxyglutarate (2-HG). 2-HG competitively inhibits... |
Explain the mechanisms of resistance after treatment with enasidenib in IDH2-mutated acute myeloid leukemia, including how to test for resistance and what next-line options exist. | 1. RESISTANCE MECHANISMS: Enasidenib targets mutant IDH2 by inhibiting the production of the oncometabolite 2-hydroxyglutarate (2-HG). Resistance arises through several mechanisms:
- Secondary IDH2 mutations: Acquired mutations in the IDH2 gene itself, such as Q316E and I319M, can alter the drug binding pocket or incre... |
Provide re-biopsy guidance for an AML patient with an IDH2 mutation progressing on Enasidenib. | 1. WHEN REPEAT BIOPSY IS INDICATED: Repeat bone marrow biopsy (with aspiration) is indicated when there is clinical evidence of disease progression: rising blast count (>5% in marrow or reappearance in blood), new extramedullary disease, or progressive cytopenias. It should also be considered if treatment response is s... |
Manage an equivocal IDH2 result from the Abbott RealTime IDH2 assay. | 1. DEFINITION OF EQUIVOCAL: For the Abbott RealTime IDH2 PCR assay, an equivocal result means the mutation signal is near the cutoff threshold, or the internal control is borderline. This occurs in <2% of cases. The assay detects specific R140 and R172 mutations; equivocal may indicate low mutant allele frequency (<5%)... |
Discuss management of a patient with IDH2 R140Q mutation and a co-occurring FLT3-ITD mutation in relapsed AML. | 1. CO-OCCURRING MUTATIONS: In IDH2-mutated AML, common co-mutations include NPM1, FLT3-ITD, DNMT3A, TET2, and RUNX1. Each may influence prognosis and treatment response.
2. PRIORITIZATION OF TARGETS: IDH2 mutations are directly targetable with enasidenib. FLT3-ITD is also targetable with FLT3 inhibitors (midostaurin, ... |
Tumor agnostic use — pan-cancer application where applicable, all solid tumors guidance | 1. IDH2 MUTATIONS AND TUMOR AGNOSTIC USE: IDH2 mutations (R140 and R172) are found in several tumor types: acute myeloid leukemia (AML), cholangiocarcinoma, glioma, chondrosarcoma, and others. However, the FDA-approved companion diagnostic (Abbott RealTime IDH2, FDA Level 1A) is specifically indicated for AML patients.... |
Write a comprehensive explanation of whether the IDH2 R140/R172 mutations are germline or somatic, and the clinical implications for the patient and family members in the context of AML and enasidenib therapy. | 1. SECTION NAME: GERMLINE VS SOMATIC — IDH2 MUTATIONS IN AML
IDH2 mutations at codons R140 and R172, as detected by the Abbott RealTime IDH2 test (Abbott Molecular, Inc.) in bone marrow or peripheral blood specimens using PCR, are almost exclusively somatic mutations in acute myeloid leukemia (AML). These mutations ar... |
Alternative testing — if FDA-approved CDx unavailable, validated LDT options | 1. ALTERNATIVE TESTING WHEN FDA-APPROVED CDx UNAVAILABLE: The Abbott RealTime IDH2 assay is a PCR-based test that detects specific IDH2 mutations. In settings where this assay is not available (e.g., many African countries, rural hospitals), validated laboratory-developed tests (LDTs) can be used. Several CLIA-certifie... |
Multidisciplinary team — how pathologist communicates result to oncologist, MDT workflow | 1. MDT WORKFLOW FOR IDH2 CDx RESULT: When the Abbott RealTime IDH2 assay is performed on bone marrow or peripheral blood, the pathologist or molecular lab reports the result as 'IDH2 mutation detected' (specify codon: R140 or R172) or 'No IDH2 mutation detected' (wildtype). For positive results, the report should inclu... |
Patient counselling — explaining biomarker testing in plain language a patient understands | 1. WHAT IS THIS TEST? This is a special blood or bone marrow test that looks for a change (called a mutation) in a gene named IDH2. This change is only in your cancer cells, not something you inherit. 2. WHY DO YOU NEED IT? Your doctor wants to know if your leukemia has this specific change because there is a pill call... |
What companion diagnostic test is required before prescribing adagrasib in KRAS G12C-mutated NSCLC? | 1. COMPANION DIAGNOSTIC TEST:
The FDA-approved companion diagnostic test required before prescribing adagrasib for KRAS G12C-mutated non-small cell lung cancer (NSCLC) is the Agilent Resolution ctDx FIRST assay (Resolution Bioscience, Inc.). This is a next-generation sequencing (NGS) assay that detects the KRAS G12C mu... |
Generate a full CDx monograph for KRAS G12C testing with adagrasib in NSCLC, covering all required sections including African context. | 1. BIOMARKER OVERVIEW:
KRAS is a GTPase that acts as a molecular switch in cell signaling pathways regulating proliferation, survival, and differentiation. The G12C mutation (a glycine-to-cysteine substitution at codon 12) locks KRAS in an active GTP-bound state, leading to constitutive activation of the RAS-MAPK signa... |
Generate a multi-turn dialogue between an oncologist and pathologist discussing a KRAS G12C liquid biopsy result for NSCLC. | [Turn 1 - Oncologist]: I have a 65-year-old patient with metastatic lung adenocarcinoma who progressed on first-line chemotherapy. I ordered a liquid biopsy to look for targetable mutations. The result shows a KRAS G12C mutation with a variant allele frequency of 5%. Is this sufficient to start adagrasib? Can I trust a... |
Create a patient scenario: a 58-year-old woman from Nigeria with advanced NSCLC and a KRAS G12C result from liquid biopsy. Include treatment decision and monitoring. | 1. PATIENT VIGNETTE:
Patient: Chioma, a 58-year-old woman in Lagos, Nigeria. She presented with persistent cough, hemoptysis, and weight loss. CT chest revealed a 4.2 cm right upper lobe mass with mediastinal lymphadenopathy and pleural effusion. She is a former smoker (20 pack-years). Bronchoscopy with biopsy confirme... |
Create a board-style multiple choice question testing knowledge of CDx for adagrasib in NSCLC. | QUESTION: A 72-year-old man with metastatic lung adenocarcinoma has progressed on first-line pembrolizumab + chemotherapy. His oncologist orders a liquid biopsy to identify targetable mutations. The result shows a KRAS G12C mutation at a variant allele frequency of 2.1% using the Agilent Resolution ctDx FIRST assay. He... |
#6: Test ordering guide — which test, where to send, what to specify, turnaround time | 1. TEST NAME: Agilent Resolution ctDx FIRST assay (Resolution Bioscience, Inc.) for detection of KRAS G12C mutation in cfDNA from plasma.
2. CLINICAL INDICATIONS: Order this test for patients with confirmed diagnosis of advanced Non-Small Cell Lung Cancer (NSCLC) who are being considered for treatment with adagrasib. ... |
#7: Result interpretation — how to interpret positive, negative, equivocal results | 1. POSITIVE RESULT: Detection of KRAS G12C mutation (p.Gly12Cys) in plasma cfDNA at an allele frequency (AF) above the assay's limit of detection (typically ≥0.1% VAF). A positive result indicates the presence of circulating tumor DNA harboring the KRAS G12C mutation. This qualifies the patient for treatment with adagr... |
#8: Negative/wildtype selection — when negative result drives treatment (critical for wildtype rows) | 1. CONCEPT OF NEGATIVE SELECTION: For KRAS G12C and adagrasib, the companion diagnostic test identifies patients who DO have the G12C mutation (positive selection). This is not a wildtype/negative selection scenario. However, it is critical to understand that a negative result means the patient may still benefit from a... |
Provide specimen handling guidance for the Agilent Resolution ctDx FIRST assay for KRAS G12C testing in non-small cell lung cancer using cfDNA from plasma. | 1. SPECIMEN REQUIREMENTS:
The FDA-approved companion diagnostic for adagrasib in KRAS G12C-mutant non-small cell lung cancer is the Agilent Resolution ctDx FIRST assay (Resolution Bioscience, Inc.), which uses cell-free DNA (cfDNA) from plasma. This is a liquid biopsy test; FFPE tissue is not the approved specimen for ... |
#10: African context — CDx device availability in Africa, alternative validated tests, cost | 1. CDx DEVICE AVAILABILITY IN AFRICA: The Agilent Resolution ctDx FIRST assay is currently not directly available as a routine test in most African countries including Kenya, Nigeria, South Africa, Ghana, Ethiopia. However, Resolution Bioscience offers a centralized testing service in the US and accepts international s... |
End of preview. Expand in Data Studio
No dataset card yet
- Downloads last month
- 32